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OSU-03012 sensitizes breast cancers to
lapatinib-induced cell killing: a role
for Nck1 but not Nck2
N Winston West1, Aileen Garcia-Vargas2, Charles E Chalfant2,3,4* and Margaret A Park2*

Abstract
Background: Lapatinib is characterized as an ErbB1/ErbB2 dual inhibitor and has recently been approved for the
treatment of metastatic breast cancer. In this study, we examined mechanisms associated with enhancing the
activity of lapatinib via combination with other therapies.
Methods: In the present studies, estrogen receptor (ER) positive and ER negative breast cancer cells were
genetically manipulated to up- or downregulate eIF2-alpha, its phospho-mutant, Nck1, or Nck2, then treated with
OSU-03012, lapatinib or the combination and assayed for cytotoxicity/cytostaticity using clonogenic assays.
Results: Treatment of breast cancer cell lines with lapatinib and OSU-03012 (a small molecule derivative of the
Cox-2 inhibitor celecoxib) induced synergistic cytotoxic/cytostatic effects. This combination therapy corresponded
to an increase in the phosphorylation of eIF2-α at serine51 and a decrease in Nck1 expression. Ectopic expression of
phospho-mutant eIF2-α (Ser51Ala) or downregulation of eIF2-α in addition to downregulation of the eIF2-α kinase
PERK inhibited the synergistic and cytotoxic effects. Furthermore, ectopic expression of Nck1, but not Nck2
abolished the decrease in cell viability observed in combination-treated cells. Downregulation of Nck1 failed to
“rescue” the ablation of the cytotoxic/cytostatic effects by the phospho-mutant of eIF2-α (Ser51Ala) demonstrating
that Nck1 downregulation is upstream of eIF2-α phosphorylation in the anti-survival pathway activated by lapatinib
and OSU-03012 treatment. Finally, co-immunoprecipitation assays indicated that eIF2-α dissociates from the
Nck1/PP1 complex after OSU-03012 and lapatinib co-treatment.
Conclusions: These data indicate that OSU-03012 and lapatinib co-treatment is an effective combination therapy,
which functions to enhance cell killing through the Nck1/eIF2 complex. Hence, this complex is a novel target for
the treatment of metastatic breast cancer.
Keywords: Breast cancer, Lapatinib, Combination therapy, Nck, eIF2-alpha

Background
Breast cancer is currently the second most common cause
of death due to cancer among women and leads to approximately 8,000 to 10,000 deaths per year [1]. Metastasis
is the main cause of breast cancer related deaths, and
these metastases are only poorly controlled with first
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generation therapies such as taxanes [2-4]. Both the ErbB2
and the ErbB1 receptors, members of the epidermal
growth factor receptor (EGFR) family, are upregulated in
many types of cancer, and overexpression of these proteins
is associated with a greater likelihood of metastasis.
Hence, this receptor family is a current therapeutic target
for the treatment of metastatic breast cancer.
The epidermal growth factor receptor family comprises
four members known as EGFR (ErbB1), Her2 (ErbB2),
ErbB3, and ErbB4. Homo- and hetero-dimerization of
these tyrosine kinase receptors occurs as a result of binding by various growth factors such as epidermal growth
factor (EGF), after which cytoplasmic tail tyrosine residues
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are phosphorylated [5,6]. Phosphorylation leads downstream to the activation of various signaling cascades such
as the extracellular-regulated kinase (ERK), and the Akt
kinase cascades. These cascades lead to propagation of
both survival and death signals [7,8]. Recently, lapatinib
(Tykerb, GSK), an ErbB1/2 inhibitor, was approved for the
treatment of metastatic breast cancer, as lapatinib is implicated in better outcomes in patients with metastases. Unfortunately, outcomes are still not ideal for patients with
metastatic disease [9,10]. Thus therapies which enhance
lapatinib-induced cell killing are needed in the clinic.
One possibility for combination therapy with lapatinib
is the small molecule inhibitor, OSU-03012. This novel
Celecoxib derivative induces death in cancer cells from
multiple lineages without inhibiting Cox-2 [11-14]. Previous analyses indicate that OSU-03012 induces cell
death partially via the activation of ER stress proteins including PKR-like ER kinase (PERK). PERK is a direct
kinase of the eukaryotic initation factor 2 (eIF2) and
phosphorylates this protein at the serine51 residue of the
alpha subunit [15,16]. Phosphorylation of eIF2-α leads to
increased expression of the pro-apoptotic transcription
factor CHOP as well as the expression of HSP70 family
chaperones. Our previous analyses demonstrated that
OSU-03012 reduced Grp78/BiP levels and increased
HSP70 levels in a PERK-dependent fashion [11,12]. The
laboratory of Dr. Chen, in general agreement with our
previous studies, has shown that inhibition of ErbB1 in
ErbB1-addicted NSCLC enhances the toxic effects of
OSU-03012, and that this is in part due to increased ER
stress signaling and increased levels of DR5 [14]. The laboratory of Dr. Paul Dent has also recently published
that OSU-03012 and lapatinib synergize in glioblastoma
cell lines, although by a different mechanism than the
one found in this manuscript [17].
In the current studies, we assessed whether OSU03012-induced killing of breast cancer cell lines was enhanced by the addition of lapatinib. We show that a decrease in adaptor protein Nck1, but not Nck2, [18,19] is
necessary for cell killing in both ER positive and ER
negative breast cancer cell lines. Furthermore, we show
that increased eIF2-α phosphorylation on Serine51 induced by the combination of OSU-03012 and lapatinib
is responsible for the synergistic effects of these agents.
Thus, the Nck1/eIF2 complex is identified in this study
as a novel target for the treatment of metastatic breast
cancer.

Methods
Cell culture

The MDA-MB-231 cell line (purchased from American
Type Culture Collection, ATCC) and the BT474 cell line
(ATCC) were maintained in RPMI (Invitrogen). ATCC
published standards are recognized by the American
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National Standards Institute (ANSI) and are compatible
with the requirements of the International Organization
for Standardization (ISO). Both cell lines were supplemented with 10% fetal bovine serum (FBS, Invitrogen) and
1% Penicillin / Streptomycin (Invitrogen). All cell lines
were maintained in a 95% air / 5% CO2 incubator at 37°C.
Cells were passaged once every 3-5 days (~90% confluence), and all experiments were performed during the first
12 passages.
Plasmids and reagents

eIF2-α expression plasmids were constructed by Ron et.
al. and purchased from Addgene (plasmid numbers
#21808 and 21807, [20]). GFP-tagged Nck1 and Nck2
plasmids were a generous gift from Dr. L. Larose
[18,19]. Antibodies to Nck1, phospho-eIF2-α (Serine51),
total eIF2-α, ERK, phospho-ERK, PTEN, phosphoPTEN, PP1, phospho-PP1 and β-actin were purchased
from Cell Signaling Technologies. Nck2 antibodies were
purchased from Novus Biologicals. siRNA molecules
against Nck1 and mutant siRNA molecules were custom
manufactured by Dharmacon. The sequence used was
previously published by Dr. W. Li and colleagues [21]. A
mutant sequence containing 9 mutations was also
manufactured as a control to ensure specificity of knockdown. Sequences are as follows (single stranded, sense):
siNck1 5’ GGC CTT CAC TCA CTG GAA A 3’; Mutant
Nck1 5’ CGC TTC CAC TGC TGA GAG A 3’. Predesigned and validated siRNA molecules to downregulate eIF2-α and control scrambled siRNA molecules
were purchased from Qiagen. siRNAs targeting ATF6
and IRE-1 were generous gifts from the laboratory of Dr.
Paul Dent.
Apoptosis assays

Cells were treated as indicated. 24 - 48 hrs later, cells were
trypsinized, washed and stained with Annexin V-PE and
propidium iodide using the ApoScreen Annexin V Apoptosis Kit (Southern Biotech) according to manufacturer’s instructions. Cells were detected using a BD FACSCanto II
and analyzed using the accompanying FACSDIVA software.
Transfection (plasmid)

Plasmid transfections were accomplished using the
Effectene system (Qiagen) according to manufacturer’s
instructions. Briefly, plasmid DNA (1 μg) was incubated
in the presence of EC buffer and a 150:18 dilution of the
Enhancer reagent for 10 minutes followed by the
addition of the Effectene reagent (at a 168:20 dilution).
Plasmid samples were incubated for a further 10 minutes
then diluted to 1 mL with complete medium and added
by single drops to the sample. Cells were allowed to accumulate the recombinant proteins for 24-48 hours. All
steps excluding the incubation of DNA, EC buffer,
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the antibody-coated beads using 200 mM glycine, pH 3.0.
Electrophoresis and western blotting procedures were
then performed as previously described.

Transfection (siRNA)

siRNA transfections were performed using the Dharmafect
1 reagent (Dharmacon) according to manufacturer’s instructions. Briefly, siRNA molecules (25 nM final concentration) were incubated in serum- and antibiotic-free
medium. Concurrently, 5 μL Dharmafect 1 reagent was incubated in serum- and antibiotic-free medium. Both tubes
were incubated at room temperature for 10 minutes then
combined and incubated at room temperature for an additional 20 minutes. siRNA was then added to cells one drop
at a time. Cells were incubated for at least 48 hours to
achieve downregulation of the target mRNA.

Isobologram analyses

Survival assays

Statistics

Clonogenic assays were performed as previously described [22]. Briefly, cells were transfected and treated as
indicated in the figure legends. Cells were then plated
onto 6-well plates at a density of 200-400 cells / well
and allowed to form colonies over the next 10-14 days.
Colonies were stained using crystal violet stain, and cells
that underwent ≥ 50 doublings were counted as a
colony.
Western blotting

Cells were plated, cultured and treated as indicated.
Cells were washed 2 times in PBS and lysed using
CelLytic (Sigma) lysis buffer supplemented 1:100 with
protease and phosphatase inhibitors (Cell Signaling) and
by sonication. Protein concentration was assessed using
Bio-Rad protein assay reagent. Equal amounts (10-20
μg) of protein were subsequently electrophoresed on 1012% SDS polyacrylamide gels and electrophoretically
transferred to PVDF membranes (Bio-Rad). Membranes
were blocked in PBS supplemented with 0.1% TWEEN20 and 5% dry milk and exposed to primary and secondary antibodies as indicated. Membranes were developed
using SuperSignal West reagents (Pierce).
Co-immunoprecipitation assays

Cells were treated as described in figure legends. Cells
were then harvested using NP-40 buffer (20 mM TrisHCl, pH 8.0; 137 mM NaCl; 2 mM EDTA; 2% NP-40;
protease and phosphatase inhibitor cocktail (added prior
to use)). Lysate was pre-incubated with protein A/G
agarose beads (1 h, 4°C with rotation). Concurrently,
Protein A/G agarose beads (Pierce) were incubated with
antibodies raised against either total eIF2-α or total PP1
(Cell Signaling). Beads were washed 3 times with NP-40
buffer and then added to cell lysates. Lysates + beads were
incubated at 4°C for 4 – 16 h with rotation and washed 3
times in NP-40 buffer. Bound proteins were released from

Isobologram analyses were performed using the method
of Chou and Talalay [23]. Briefly, colony formation assays were performed using stepwise increasing concentrations of OSU-03012 and lapatinib either singly or in
combination (1 μM, 2 μM and 3 μM both in single and
in combination treatments). Analyses were then
performed using the Calcusyn program (Biosoft). Fraction affected (FA) was calculated and the combination
index (CI) was then used as a measure of synergy.

All P values refer to paired student’s t-tests; differences
with p≤0.05 were considered significant. Analyses were
performed using the Sigmaplot software.

Results and discussion
OSU-03012 and lapatinib synergize to induce cell death
in both ER positive and ER negative breast cancer cell
lines. As stated previously, one possibility for combination therapy with the FDA-approved drug lapatinib is
the small molecule OSU-03012 as this novel Celecoxib
derivative induces cell death in cancer cells from multiple lineages [11-14]. In our initial studies, cell death
(via annexin V-PE) of MDA-MB-231 (ER negative, [24])
and BT474 (ER positive, [24]) breast cancer cells was
assessed after co-treatment with OSU-03012 and
lapatinib. Neither OSU-03012 nor lapatinib at 1 or 2 μM
(well below the maximum tolerated dose) induced significant increases in cell death when compared to control conditions (Figure 1A-C). However, treatment of
BT474 cells with single agents at 3 μM resulted in decreases in clonogenic capacity when compared to controls (Figure 1A). Treatment with the combination at all
concentrations tested showed a greater than additive effect (See Table 1, Figure 1). This effect was confirmed by
repeating the experiment and demonstrating a decrease
in the survival of cells treated with the combination at 2
μM (see Figure 1D-E). Synergy was confirmed by survival assays followed by isobologram analyses (Table 1,
[23]). A combination index (CI) value of less than 1 indicates synergistic effects, whereas a CI value of 1 indicates an additive effect and a CI value of greater than 1
indicates antagonistic effects. These data demonstrate
that OSU-03012 and lapatinib act synergistically to induce cell death in both ER positive and ER negative
breast cancer cell lines and provided a rationale for
treatment of cell lines at 2 μM for the remainder of the
studies.
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Figure 1 OSU-03012 and lapatinib act to kill ER-positive and ER-negative breast cancer cells in combination. A, D-E: ER-positive BT474
and ER negative MDA-MB-231 cell lines were treated with the indicated concentrations of OSU-03012 and lapatinib (A) or 2 μM lapatinib OSU03012 and 2 μM lapatinib (D-E) for 48 h. Cells were then singly plated onto 6-well plates to assay for clonogenic capacity. B-C: BT474 and MDAMB-231 cells were treated with 2 μM OSU-03012 (OSU) or 2 μM lapatinib (Lap) or the combination, incubated for 48 h, then assayed using
Annexin V/PI for cell death. All measurements are ± SEM. * indicates a p < 0.05 when compared to the vehicle-treated condition.

Interestingly, OSU-03012 and lapatinib combination
therapy was more effective against MDA-MB-231 cells
than BT474 cells. Therefore, our findings argue that
targeting ER stress proteins may increase the efficacy of
traditional therapies specifically for metastatic breast
cancers [11-13] since the BT474 cell line is less invasive
than the triple negative MDA-MB-231 cell line [25,26].
Specifically, we found a greater decrease in cell viability
and a lower CI value for synergy between OSU-03012
and lapatinib in the triple negative cell line MDA-MB-

231 (harvested from the metastatic pleural ascites) than
in ErbB2-amplified BT474 cell line (harvested from a
primary site). These findings provide support for the hypothesis that OSU-03012 and lapatinib in combination
may be more effective against metastatic breast cancers
than non-metastatic breast cancers. These results are
also in line with recent studies by Sanz-Pamplona et. al.,
which showed that upregulation of GRP94, an ER stress
protein, is an effective marker for brain metastases of
breast cancers [27], and others [28], which showed that
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(PERK, [14] see Figure 2), and that the ER stress response
is important in breast cancer tumorigenesis [27,28]. We
therefore determined whether downregulation of the three
main ER stress sensors (PERK, IRE-1α and ATF6) decreased cell death induced by OSU-03012 and lapatinib in
combination. The involvement of PERK in lapatinib/OSU03012-induced cytotoxicity was confirmed in these studies.
Other ER stress sensors did not protect against lapatinib/
OSU-03012-induced cytotoxicity/cytostaticity (ATF6), or
had a small protective effect (IRE-1α, see Figure 2). We
therefore chose to focus on PERK-mediated effects for the
remainder of these studies. PERK is a direct kinase of the
eukaryotic initation factor 2 (eIF2), phosphorylating this
protein at the serine51 residue of the alpha subunit [15].
Thus, the phosphorylation state of eIF2-α was assessed in
these studies as an indicator of ER stress. Surprisingly,
treatment of breast cancer cells with OSU-03012 or
lapatinib alone only affected the phospho-state of eIF2-α
on Ser51 in a minor fashion (Figure 3). Importantly, the
phosphorylation of this protein was increased significantly
after co-treatment lapatinib and OSU-03012.
Since eIF2-α phosphorylation on Ser51 was upregulated
by combination therapy (Figure 3), the role of eIF2-α was
examined in the synergistic killing of breast cancer cells.
As shown in Figure 4A and B, knockdown of eIF2-α completely ablated the decrease in survival induced by OSU03012 and lapatinib. Importantly, ectopic expression of
the inactive Ser51Ala phospho-mutant attenuated cell
death induced by the combination treatment in contrast
to ectopic expression of wild-type eIF2-α (Figure 4C and
D). These data demonstrate that eIF2-α phosphorylation
on serine51 is a central event in the induction of cell death
induced by OSU-03012 and lapatinib.
PTEN [33] and protein phosphatase 1 (PP1, [34]) are
two phosphatases whose activities are linked to eIF2-α
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other ER stress markers are upregulated during suspension conditions.
Our data demonstrating that MDA-MB-231 cells are
more sensitive to the combination of OSU-03012/
lapatinib are also in general agreement with the findings
in Figure 7B, that PP1 associates significantly less with
eIF2-α after OSU/lapatinib treatment in MDA-MB-231
cells than in BT474 cells. While PTEN, Raf, and Akt
levels and mutation status appear to be similar in both
MDA-MB-231 and BT474 cells [29-31], BT474 cells express a constitutively active form of PI3KCA (K111N), in
addition to overexpressing ErbB2 [32]. It may be that
upregulation of the PI3K/Akt pathway represents a potential pathway of resistance for cell lines treated with
OSU-03012/lapatinib in combination. Therefore, inhibitors of the PI3K pathway should be combined with
OSU-03012/lapatinib in future studies.
Phosphorylation of eIF2-α at serine51 specifically induces cell death in response to OSU-03012 and lapatinib
via protein phosphatase-1. Previous analyses indicate
that OSU-03012 induces cell death partially via the activation of ER stress proteins, including PKR-like ER kinase
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Table 1 Isobologram analysis of MDA-MB-231 and BT474
cell lines indicates that the drugs are synergistic in
multiple breast cancer lines
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Figure 2 ER stress via PERK activation may be responsible for lapatinib/OSU-03012-induced cytotoxicity/cytostaticity. A-B: MDA-MB-231
cells, 24 h after plating, were transfected with the indicated siRNA. After a 24 h incubation, cells were either plated singly onto 6-well plates and
allowed to attach overnight (A) or harvested for immunoblotting to ensure knockdown (B). Cells in (A) were treated with vehicle or OSU-03012/
lapatinib (48 h) then media was replaced and colonies were allowed to develop over the next 10-14 d. Colonies were counted using crystal violet
stain and the number of colonies was graphed (n=3, *=p<0.05).
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Total eIF2α

Total eIF2α

Figure 3 Phosphorylation of eIF2-α indicates ER stress signaling in MDA-MB-231 and BT474 cells after treatment with OSU-03012 and lapatinib.
MDA-MB-231 cells and BT474 cells (1 x 106) were subjected to vehicle (DMSO, Ctr), OSU-03012 (2 μM), lapatinib (2 μM) or the combination as indicated for
3 h. Cells were then lysed and protein extracts (10-20 μg) were subjected to SDS PAGE followed by western immunoblotting for the indicated proteins.

Figure 4 The role of eIF2-α phosphorylation in cell death induced by OSU-03012 and lapatinib. A-B: MDA-MB-231 (A) or BT474 (B) cells
(5 x 105) were transfected with the indicated siRNA molecules and incubated for 48 h. Cells were then treated with either vehicle (Veh) or the
combination of OSU-03012 (2 μM) and lapatinib (2 μM) (combo) as indicated and either subjected immunoassays (bottom panels) or plated for
clonogenic capacity (top graphs). Numbers indicated are percent control (e.g. Veh). C-D: MDA-MB-231 cells (5 x 105) were transfected with a
control vector (Vector), wild-type (WT) or the Ser51Ala mutant (S51A) eIF2-α plasmids. After a further 24 h cells were plated onto 6-well plates to
assay for clonogenic capacity (D) or subjected to immunoblotting as described in Materials and Methods (C). Cells were treated with either
vehicle (Veh, DMSO) or OSU-03012 (2 μM) and lapatinib (2 μM) in combination (combo) for 24 h (D) or 3 h (C). Colonies were allowed to develop
for the next 10-14 days. * indicates a p < 0.05 with respect to vehicle-treated cells. E: MDA-MB-231 cells (1 x 106) were plated and treated with
the indicated drugs (Vehicle (Ctr, DMSO), OSU-03012 (OSU, 2 μM), lapatinib (Lap, 2 μM) or the combination (Combo)). Three hours later, cells were
harvested and subjected to immunoblotting. Samples were probed with the indicated antibodies (see Materials and Methods).
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phosphorylation. Thus, we assessed the activity of these
phosphatases as upstream determinants of OSU-03012/
lapatinib-induced eIF2-α phosphorylation. First, the
phospho-status of PTEN was examined as an indicator
of activation, but no increases were observed for the
phosphorylation of PTEN (Figure 4E). Instead, the phosphorylation pattern was similar to the pattern of total
PTEN expression. Hence, enhanced PTEN activity is unlikely affecting OSU-03012- and lapatinib-induced cell
death/reduced survival. In Figure 4E, we observed that the
phosphorylation of the PP1 was significantly increased indicating a decrease in the activity of PP1 (Figure 4E, [34]).
Thus, with regards to upstream events leading to eIF2-α
activation, PP1, but not PTEN, is a likely candidate responsible for the dephosphorylation of eIF2-α induced by
OSU-03012/lapatinib in combination.
Taken together, the data in Figures 3 and 4 showed that
OSU-03012/lapatinib in combination upregulated ER
stress-related pathways, and that downregulation of eIF2α phosphorylation at serine51 completely ablated cell death
induced by OSU-03012/lapatinib and demonstrated that
PP1 was a likely candidate for eIF2-α dephosphorylation.
ER stress aggravators (ERSAs) are a relatively recent
addition to our arsenal of therapeutic agents for the treatment of cancer. There are multiple reports [27,28,35] that
ER stress factors are upregulated in many types of cancer
suggesting that these pathways may be ones to which cancers may become addicted and therefore represent good targets for treatment. OSU-03012 represents one ERSA which
may be used to enhance ER stress pathways in cancer cells.
This may activate a response in which the cancer cell shifts
from using ER stress signaling as a survival mechanism to
an apoptotic one. Our findings demonstrate that eIF2-α
phosphorylation is a major event in the cell death pathways
induced during treatment with OSU-03012/lapatinib. Furthermore, the question whether other molecules that induce
ER stress will also enhance lapatinib-induced cell killing
should be pursued in light of these studies.
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Figure 5 Upstream signaling responsible for eIF2-α
phosphorylation: A role for Nck1. A-B: MDA-MB-231 cells and
BT474 cells were treated with vehicle (Ctr, DMSO), OSU-03012 (OSU,
2 μM), lapatinib (Lap, 2 μM) or the combination (Combo) for 3 h,
then harvested for immunoblotting assays as described in Materials
and Methods. Membranes were probed with the indicated
antibodies. C: MDA-MB-231 cells (5 x 105) were transfected with
plasmids to express either GFP-Nck1 or GFP-Nck2 as described. After
an additional 24 h, cells were treated with the combination of OSU03012 and lapatinib as indicated for 24 h (upper graphs) or 3 h
(lower panels), and then either plated onto 6-well dishes and
allowed to form colonies (graphs represent percent control) or
harvested for immunoblotting assays and probed with the indicated
antibodies. * indicates a p<0.05.

Nck1, but not Nck2 is intrinsic to OSU-03012/lapatinibinduced cell death

PP1 has been found by Larose et al [18,19] in a complex
containing both eIF2 and the protein Nck1. Nck1 (or
Nckα), an SH-only adaptor protein, was originally characterized as playing a role in driving cell motility [36], a
hallmark of metastatic cancer. Nck1 binds to eIF2-β,
preventing the phosphorylation of eIF2-α specifically on
Serine51, and dissociation of Nck1 leads to increased
levels of eIF2-α phosphorylation. Thus, we examined the
role of Nck1 in the enhanced phosphorylation of eIF2-α
on Serine51. A robust, greater-than-additive decrease in
the levels of Nck1 was observed in combination-treated
samples (See Figure 5A,B) in contrast to cells treated
with a single drug. Nck2 (also known as Nckβ)

expression did not follow the same pattern indicating a
novel differential role for these two family members in
OSU-03012- and lapatinib-induced cell killing.
Next, we examined the role of Nck1 in the cell death and
eIF2 Ser51 phosphorylation induced by the combination of
OSU-03012 and lapatinib. The decrease in both clonogenic
capacity and eIF2-α phosphorylation in MDA-MB-231 cells
after OSU-03012 and lapatinib combination treatment was
“rescued” by the ectopic expression of Nck1 (see Figure 5C),
but not by ectopically expressing Nck2. Furthermore, Nck1,
when co-expressed with wild-type eIF2-α, ablates the increase in cell death induced by OSU-03012 and lapatinib
indicating a role in the same pathway for this protein (See
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Figure 6 Nck1, but not Nck2 expression ablates the increase in cell death induced by OSU-03012 and lapatinib. A-D: MDA-MB-231 cells
(A, B), or BT474 cells (C, D) (5 x 105) were co-transfected with either wild-type eIF2-α and the two Nck isoforms (A, C), or the S51A phosphomutant and the two Nck isoforms (B, D). Cells were allowed to incubate for 24 h to induce ectopic expression, and then treated with either
vehicle (indicated with a -), or the combination of OSU-03012 and lapatinib (2 μM each, indicated with a +). Cells were either harvested after a 3
h treatment for western blotting as described in Materials and Methods (bottom panels), or plated singly onto 6-well plates to assay for
clonogenic capacity (upper graphs). Cells were treated with OSU-03012 (2 μM) and lapatinib (2 μM) for 24 h, and then allowed to form colonies
for 10-14 days. Total colony counts were graphed. * denotes a p-value of <0.05.

Figure 6A and C). In contrast, ectopic co-expression of the
Ser51Ala phospho-deficient mutant of eIF2-α with either
Nck1 or Nck2 ablated all cell death induced OSU-03012
and lapatinib in combination (See Figure 6B and D). Coexpression of Nck2 and wild-type eIF2-α did not affect the
levels of cell death indicating that this pathway is specific
for Nck1.
Finally, in agreement with our hypothesis that decreased Nck1 expression is upstream to the increase in
eIF2-α phosphorylation, we showed that downregulation
of Nck1 was insufficient to re-sensitize BT474 cells to
the ablation of OSU-03012 and lapatinib-induced cell

death when the phospho-mutant of eIF2-α is ectopically
expressed (Figure 7A). In addition, OSU-03012/lapatinib
in combination induces a decrease in the association of
eIF2-α with PP1 (Figure 7B). Taken together, these data
demonstrate that a major mechanism of cell death via
the combination of OSU-03012 and lapatinib is a decrease in Nck1 expression followed by upregulation of
eIF2-α phosphorylation, and thus ER stress-related cell
death (Figure 7C).
Larose and colleagues [18,19] found that Nck1 forms a
complex with eIF2 and PP1. Dissociation of this complex
can lead to eIF2-α phosphorylation at serine51 and a
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Figure 7 Nck1 is upstream of eIF2-α phosphorylation in the cell death induced by the combination of OSU-03012 and lapatinib. A:
BT474 cells (5 x 105) were co-transfected with the Ser51Ala eIF2-α mutant and GFP-Nck1. Cells were allowed to incubate for 24 h to induce
ectopic expression then treated with either vehicle (indicated with a -), or the combination of OSU-03012 and lapatinib (2 μM each, indicated
with a +). Cells were either harvested for western blotting as described previously (lower panel), or plated into 6-well plates to assay for
clonogenic capacity as described previously (upper graph). Graphs represent total colony number. * denotes a p-value of <0.05. B: BT474 (upper
panel) and MDA-MB-231 (lower panel) cells were treated with either vehicle (Veh) or OSU-03012 and lapatinib in combination (combo). PP1 was
immunoprecipitated and the resulting membranes were immunoblotted with eIF2α and PP1. C: Our data indicate that Nck1 and PP1, which are
originally in a complex with eIF2 are dissociated after treatment with the combination of OSU-03012 and lapatinib. This event frees eIF2-α to
become phosphorylated by one of many upstream kinases such as PERK, leading to ER stress and eventual cell death.

decrease in protein translation. eIF2-α may also be phosphorylated at serine51 by the ER resident kinase PERK
during ER stress. Since we show in Figure 2 that OSU03012/lapatinib in combination induces ER stress in part
by PERK activation, we performed studies aimed at determining the role of Nck1 in ER stress-induced cell death by
OSU-03012 and lapatinib in combination. Our studies
showed that ectopic expression of Nck1 abolished the cell
death induced by OSU-03012/lapatinib. Furthermore,
upregulation of Nck1 “rescues” the cell death induced by
wild-type eIF2-α overexpression. Thus, the studies
reported here demonstrate that the Nck1/eIF2 complex is
a key point at which lapatinib and OSU-03012 act to synergistically kill metastatic breast cancer cells, and generally
support Larose’s findings that PP1 is important in this
complex.
In contrast to our findings implicating a PP1, Nck1 and
eIF2-containing complex in the cytotoxicity/cytostaticity induced by OSU-03012/lapatinib, the Dent laboratory has recently published that lapatinib enhances OSU-03012
-induced cell killing in glioblastoma models and that this
phenomenon occurs via an ErbB/Akt/PTEN pathway [17].
MDA-MB-231 and BT474 cells as well as GBM6 and
GBM12 (used in [17]) cell lines are all PTEN wild-type.
Therefore, cancer-type-specific pathways may be responsible

for this apparent contradiction. Our data suggest that further experiments may need to take these cancer-specific differences into account when designing therapeutic regimens.
Recently, EGFR-mediated Nck1/Rap1 activation has
been shown to upregulate metastasis in a model of
metastatic pancreatic carcinoma without affecting primary tumor growth [37]. These findings raise two intriguing possibilities: 1) Nck1 downregulation may be a
singularly efficacious inducer of cell death specifically for
metastatic breast cancer cells, and 2) eIF2 may play a
role in the metastatic process. We observe a small, but
insignificant decrease in the viability of BT474 cells (a
non-invasive cell line, see Figure 7) after RNAi-mediated
inhibition of Nck1, which may be indicative that inhibition of Nck1 alone may induce cell death in more invasive cell lines. In addition, we observe that Nck1 is
downregulated only with the combination treatment in
MDA-MB-231 (a more invasive cell line) cells even
though eIF2-α phosphorylation is upregulated in samples treated with single drugs. eIF-4E, the mRNA capbinding protein essential for the initiation of translation,
has been found to contribute to malignancy by enabling
translation of select mRNAs that encode proteins involved in growth, angiogenesis, survival and malignancy
[38]. Interestingly, ER stress signaling and eIF2-α
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phosphorylation have been linked to drug resistance and
survival in occult dormant carcinoma cells [39]. However, eIF2-α has never before been characterized specifically as a regulator of metastasis. Therefore, studies
aimed at characterizing the involvement of eIF2 in metastasis, both in vivo and in vitro, are a natural continuation of these findings as are studies aimed at examining
the potential of Nck1 inhibition as a therapy specific for
metastatic breast cancer.

Conclusions
Combination therapies are especially useful in the treatment of many cancers, in part due to the ability of separate drugs to target multiple separate survival pathways
upregulated in many cancer lineages [40]. In these studies, we have used the concept of combination therapies
to delineate the interaction between OSU-03012 and
lapatinib. We showed that OSU-03012 and lapatinib
synergized to induce cell death in both an ER positive
and an ER negative breast cancer cell line suggesting
that this therapeutic model may be effective against a
variety of breast cancer phenotypes. We also demonstrated that eIF2-α phosphorylation is a central event in
the synergistic cytotoxicity/cytostaticity induced by the
combination therapy of OSU-03012 and lapatinib, and
that this event is partially mediated by the protein phosphatase PP1/Nck/eIF2 complex.
These studies describe a novel mechanism of cytotoxicity/cytostaticity via Nck1-mediated eIF2-α phosphorylation for the combination of lapatinib and OSU-03012.
We conclude that OSU-03012 and lapatinib act synergistically to induce cell death via the downregulation of
Nck1/PP1 and the subsequent dissociation of this complex from eIF2-α. We also conclude that this dissociation likely leads to a PP1-mediated enhancement of
eIF2-α phosphorylation at serine51, a marker for ER
stress and a central event in the induction of cell death
by OSU-03012/lapatinib. This work additionally identifies the Nck1/PP1/eIF2-α as a novel target for inhibition
for future therapies.
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